How BioMarin Beat Expectations in Q3

2020 is looking like a year to forget for BioMarin Pharmaceutical (NASDAQ:BMRN). The decision by the Food and Drug Administration (FDA) to not approve Roctavian (valoctocogene roxaparvovec) in treating severe hemophilia A rocked the company and its share price.